Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Kono, Koji ^a,b   Mimura, Kousaku ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Calreticulin; Cancer testis antigens; Chemoradiation; Esophageal squamous cell carcinoma; Hmgb1; Immunogenic cell death

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ARTICLE; CANCER SURVIVAL; CELLULAR IMMUNITY; CHEMORADIOTHERAPY; ESOPHAGUS CANCER; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; SURVIVAL TIME; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT;

EID: 84885735245     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22197     Document Type: Article

References (10)

1. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2:277-88; PMID:12001989; http://dx.doi.org/10.1038/nrc776.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267:1456-62; PMID:7878464; http://dx.doi.org/10.1126/science.7878464.
3. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220:47-59; PMID:17979839; http://dx.doi. org/10.1111/j.1600-065X.2007.00573.x.
4. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622.
5. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010; 16:3100-4; PMID:20421432; http://dx.doi.org/10.1158/1078-0432.CCR-09-2891.
6. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29:482-91; PMID:19881547; http://dx.doi. org/10.1038/onc.2009.356.
7. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi. org/10.1038/nm1523.
8. Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008; 99:1448-54; PMID:18452554; http://dx.doi.org/10.1111/j.1349-7006.2008.00844.x.
9. Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009; 100:1502-9; PMID:19459850; http://dx.doi. org/10.1111/j.1349-7006.2009.01200.x.
10. Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 2012; 72:3967-76; PMID:22700877; http://dx.doi. org/10.1158/0008-5472.CAN-12-0851.